Structural and functional correlation of ADAMTS13

Current Opinion in Hematology

Volumn 14, Issue 3, 2007, Pages 270-276

  Dong, Jing Fei ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

ADAMTS13; Thrombotic thrombocytopenic purpura; Von Willebrand factor

Indexed keywords

ANTICOAGULANT AGENT; AUTOANTIBODY; BARIUM CHLORIDE; MUTANT PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT VON WILLEBRAND FACTOR CLEAVING PROTEINASE; UNCLASSIFIED DRUG; UREA; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE ANTIBODY;

AMINO ACID SEQUENCE; ANTICOAGULANT THERAPY; CARBOXY TERMINAL SEQUENCE; DELETION MUTANT; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME STRUCTURE; ENZYME SUBSTRATE; GENE MUTATION; HUMAN; IONIC STRENGTH; KNOCKOUT MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ANALYSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE DEFICIENCY;

ANIMALS; METALLOENDOPEPTIDASES; MICE; MUTATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; VON WILLEBRAND FACTOR;

EID: 34247109995     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3280d35820     Document Type: Review

References (58)

1. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87:4223-4234.
2. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87:4235-4244.
3. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98:1662-1666.
4. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413:488-494.
5. Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276:41059-41063.
6. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc 1924; 24:21.
7. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307:1432-1435.
8. Moake JL, Turner NA, Stathopoulos NA, et al. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988; 71:1366-1374.
9. Zheng X, Nishio K, Majerus EM, Sadler JE. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem 2003; 278:30136-30141.
10. Majerus EM, Anderson PJ, Sadler JE. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem 2005; 280:21773-21778.
11. Dong JF, Moake JL, Bernardo A, et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003; 278:29633-29639.
12. Ai J, Smith P, Wang S, et al. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem 2005; 280:29428-29434.
13. Tao Z, Wang Y, Choi H, et al. Cleavage of ultra-large multimers of Von Willebrand factor by C-terminal truncated mutants of ADAMTS-13 under flow. Blood 2005; 106:141-143.
14. Tao Z, Peng Y, Nolasco L, et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood 2005; 106:4139-4145.
15. Zhang W, Motto DG, Ginsburg D. ADAMTS13 binds VWF via its C-terminal CUB2 domain [abstract]. Blood 2004; 104:126.
16. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100:4033-4039.
17. Sutherland JJ, O'Brien LA, Lillicrap D, Weaver DF. Molecular modeling of the von Willebrand factor A2 domain and the effects of associated type 2A von Willebrand disease mutations. J Mol Model (Online) 2004; 10:259-270.
18. Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet glycoprotein Ibα to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci USA 2004; 101:10578-10583.
19. Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004; 103:607-612.
20. Wu JJ, Fujikawa K, McMullen BA, Chung DW. Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. Proc Natl Acad Sci USA 2006; 103:18470-18474. This study identifies a core binding sequence on the VWF A2 domain that binds ADAMTS13 and demonstrates that the interaction is electrostatic in nature.
21. Zanardelli S, Crawley JT, Chion CK, et al. ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem 2006; 281:1555-1563.
22. Gao W, Anderson PJ, Majerus EM, et al. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci USA 2006; 103:19099-19104. Experimental results reported in this study narrow down the ADAMTS13 binding sequence in the VWF A2 to nine amino acids in the minimal binding sequence of 73 amino acids and indicate that the sequence interacts with an exosite in the spacer domain of ADAMTS13.
23. Anderson PJ, Kokame K, Sadler JE. Zinc and calcium ions cooperatively modulate ADAMTS13 activity. J Biol Chem 2006; 281:850-857. This study suggests that barium acts to release chelated calcium and demonstrates lower binding of ADAMTS13 for the 73-mer A2 peptide than VWF multimers.
24. Hassenpflug WA, Budde U, Obser T, et al. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood 2006; 107:2339-2345. The study demonstrates a role of the VWF A2 mutations in regulating VWF proteolysis.
25. Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129:93-100.
26. De Cristofaro R, Peyvandi F, Palla R, et al. Role of chloride ions in modulation of the interaction between von Willebrand factor and ADAMTS-13. J Biol Chem 2005; 280:23295-23302.
27. De Cristofaro R, Peyvandi F, Baronciani L, et al. Molecular mapping of the chloride-binding site in von Willebrand factor (VWF): energetics and conformational effects on the VWF/ADAMTS-13 interaction. J Biol Chem 2006; 281:30400-30411. Two sequential studies (with [26]) convincingly demonstrate how chloride affects VWF proteolysis by being an antagonist to urea in exposing the cleavage site for ADAMTS13.
28. Bongers TN, de Maat MP, Dippel DW, et al. Absence of Pro475Ser polymorphism in ADAMTS-13 in Caucasians. J Thromb Haemost 2005; 3:805.
29. Ruan C, Dai L, Su J, et al. The frequency of P475S polymorphism in von Willebrand factor-cleaving protease in the Chinese population and its relevance to arterial thrombotic disorders. Thromb Haemost 2004; 91:1257-1258.
30. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002; 99:11902-11907.
31. Shelat SG, Ai J, Zheng XL. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. Semin Thromb Hemost 2005; 31:659-672.
32. Peyvandi F, Lavoretano S, Palla R, et al. Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Hum Mutat 2006; 27:330-336.
33. Donadelli R, Banterla F, Galbusera M, et al. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 96:454-464. Data present in this study illustrate the predominant synthesis/secretion defects associated with ADAMTS13 mutations associated with familiar TTP.
34. Feys HB, Liu F, Dong N, et al. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost 2006; 4:955-962.
35. Plaimauer B, Fuhrmann J, Mohr G, et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 2006; 107:118-125. This is one of a few studies showing how polymorphisms interact with mutations in regulating ADAMTS13 biosynthesis.
36. Plaimauer B, Zimmermann K, Volkel D, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002; 100:3626-3632.
37. Zhou W, Inada M, Lee TP, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 2005; 85:780-788.
38. Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106:922-924.
39. Niiya M, Uemura M, Zheng XW, et al. Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J Thromb Haemost 2006; 4:1063-1070. This study demonstrates that ADAMTS13 increases its release through the storage pool, but not transcription, a conclusion consistent with [40].
40. Claus RA, Bockmeyer CL, Kentouche K, et al. Transcriptional regulation of ADAMTS13. Thromb Haemost 2005; 94:41-45.
41. Turner N, Nolasco L, Tao Z, et al. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 2006; 4:1396-1404. The study shows that vascular endothelial cells synthesize and release ADAMTS13. The secreted metalloprotease is primarily membrane-bound.
42. Shang D, Zheng XW, Niiya M, Zheng XL. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 2006; 108:2207-2215. The study shows that endothelial cells release and sort ADAMTS13 to the lumen site of cells and the polarity is determined by lipid raft-mediated signals through the CUB domain.
43. Suzuki M, Murata M, Matsubara Y, et al. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun 2004; 313:212-216.
44. Liu L, Choi H, Bernardo A, et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 2005; 3:2536-2544.
45. Klaus C, Plaimauer B, Studt JD, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004; 103:4514-4519.
46. Luken BM, Kaijen PH, Turenhout EA, et al. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4:2355-2364.
47. Rieger M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106:1262-1267.
48. Luken BM, Turenhout EA, Kaijen PH, et al. Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost 2006; 96:295-301. The authors have mapped the core epitopes of ADAMTS13 autoantibodies to two short sequences in the spacer domain.
49. Soejima K, Matsumoto M, Kokame K, et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 2003; 102:3232-3237.
50. Zhou W, Dong L, Ginsburg D, et al. Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy? J Biol Chem 2005; 280:39934-39941.
51. Shelat SG, Smith P, Ai J, Zheng XL. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 2006; 4:1707-1717.
52. Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107:528-534. This is the first study to demonstrate ADAMTS13 deficiency in sepsis-induced disseminated intravascular coagulation and to detect proteolytic fragments of the metalloprotease in patients' plasma.
53. Nguyen TC, Liu A, Liu L, et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Hematologica 2007; 91:121-124. This study links acquired ADAMTS13 deficiency to increased VWF adhesion activity and severe thrombocytopenia in sepsis patients.
54. Schnog JJ, Hovinga JA, Krieg S, et al. ADAMTS13 activity in sickle cell disease. Am J Hematol 2006; 81:492-498. This is the first study to show that ADAMTS13 deficiency may contribute to vasoocclusion crisis in patients with sickle-cell disease.
55. Matsumoto M, Kawaguchi S, Ishizashi H, et al. Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress. Pathophysiol Haemost Thromb 2005; 34:35-40.
56. Bongers TN, de Maat MP, van Goor ML, et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006; 37:2672-2677.
57. Donadelli R, Orje JN, Capoferri C, et al. Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood. Blood 2006; 107:1943-1950. This study demonstrates strongly the antithrombtic potential of recombinant ADAMTS13 in vitro.
58. Chauhan AK, Motto DG, Lamb CB, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006; 203:767-776. This study shows the formation of ULVWF strings in mouse models and demonstrates the antithrombotic effects of recombinant ADAMTS13.